Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 601 of 5804
-
New combo therapy aims to stall prostate cancer spread
Disease control Recruiting nowMulticenter, open-label, parallel-group, phase II randomized study in patients with oligometastatic prostate cancer with 1-3 asymptomatic metastases of the soft tissue or bone. Eligible patients will be randomized at 1:1 ratio to Stereotactic Radiotherapy followed by Lu-PSMA (arm…
Phase: PHASE2 • Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Could a High-Fat diet help fight brain cancer?
Disease control Recruiting nowThis is a Phase 2, randomized two-armed, multi-site study of 170 patients with newly diagnosed glioblastoma multiforme. Patients will be randomized 1:1 to receive Keto Diet, or Standard Anti-Cancer Diet. All patients will receive standard of care treatment for their glioblastoma.…
Phase: PHASE2 • Sponsor: Cedars-Sinai Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New hope: drug combo targets HIV-Linked cancers
Disease control Recruiting nowBackground: Non-Hodgkin lymphoma (NHL) is the most common cancer among people living with HIV in the United States. People with HIV are up to 17 times more likely to get NHL than people who do not have HIV. The disease may also be different in these two groups. More study is nee…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
CF drug shows promise for toddlers in Final-Stage trial
Disease control CompletedThis study will evaluate the pharmacokinetics (PK), safety, tolerability, pharmacodynamics (PD), and efficacy of ELX/TEZ/IVA in CF subjects 12 to less than (\<) 24 months of age.
Phase: PHASE3 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New pill aims to stop dangerous blood pressure drops in rare brain disease
Symptom relief OngoingThis is a Phase 3, multi-center, randomized withdrawal study to evaluate the efficacy and durability of ampreloxetine in participants with MSA and symptomatic nOH after 20 weeks of treatment. This study includes 4 periods: Screening, open label, randomized withdrawal, and long-te…
Phase: PHASE3 • Sponsor: Theravance Biopharma • Aim: Symptom relief
Last updated Jun 26, 2026 13:24 UTC
-
One-Week radiation blasts recurrent breast cancer, spares healthy tissue
Disease control Recruiting nowBreast-conserving surgery followed by re-irradiation with partial breast irradiation (rPBI) has recently been found to be a safe alternative to mastectomy for women who have undergone prior whole breast radiation. By reducing the volume of tissue receiving radiation, rPBI has bee…
Phase: NA • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Magic mushroom compound tested to calm cancer anxiety
Symptom relief CompletedThis phase I/II trial tests the safety and side effects of psilocybin in combination with therapy for the treatment of patients with metastatic cancer and symptoms of anxiety and/or depression. Psilocybin is a substance being studied in conjunction with therapy for the treatment …
Phase: PHASE1, PHASE2 • Sponsor: University of Washington • Aim: Symptom relief
Last updated Jun 27, 2026 07:56 UTC
-
Magic mushroom therapy shows promise for depression in small trial
Symptom relief CompletedThe primary objectives of this clinical investigation are to (1) determine the acceptability and feasibility of joining psilocybin-assisted therapy with cognitive-behavioral therapy (PA-CBT) for patients with depression, (2) optimize CBT to most effectively integrate the psilocyb…
Phase: PHASE1 • Sponsor: University of California, Los Angeles • Aim: Symptom relief
Last updated Jun 27, 2026 12:35 UTC
-
Two-Drug cocktail aims to beat back rare bone marrow cancers
Disease control OngoingThis phase II trial tests whether decitabine and cedazuridine (ASTX727) in combination with venetoclax work better than ASTX727 alone at decreasing symptoms of bone marrow cancer in patients with chronic myelomonocytic leukemia (CMML), myelodysplastic syndrome/myeloproliferative …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New immunotherapy combo shows promise for advanced liver cancer
Disease control OngoingThis study will assess the safety and efficacy of Single Tremelimumab Regular Interval Durvalumab (STRIDE) as first-line therapy in participants with advanced unresectable HCC.
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New drug cocktail shows promise for tough lung cancer mutation
Disease control OngoingThis study is designed to evaluate the efficacy and safety of Pembrolizumab in combination with Bevacizumab and chemotherapy in advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutation.
Phase: PHASE2 • Sponsor: Shanghai Chest Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New lupus pill shows promise in Mid-Stage trial
Disease control OngoingThe purpose of this study is to assess the clinical efficacy, safety, PK, and PD of multiple dose levels of ESK-001 compared with placebo in adult patients with SLE.
Phase: PHASE2 • Sponsor: Alumis Inc • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New lupus pill shows promise in major trial
Disease control OngoingThe goal of this clinical trial is to see how well cenerimod reduces symptoms of Systemic Lupus Erythematous in adult patients with moderate to severe symptoms. The main questions it aims to answer are: * How well cenerimod works on top of the treatment already being administere…
Phase: PHASE3 • Sponsor: Viatris Innovation GmbH • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New combo aims to mop up hidden cancer cells after myeloma transplant
Disease control OngoingThis is a single-center, single-arm, phase II study that will enroll multiple myeloma (MM) patients with persistent bone marrow minimal residual disease (MRD) post autologous stem cell transplant (ASCT) irrespective of the International Myeloma Working Group (IMWG) response.
Phase: PHASE2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New cell therapy takes on recurrent ovarian cancer
Disease control OngoingThis is a phase 2, open-label, randomized, non-comparative clinical trial to evaluate the clinical outcome of ADP A2M4CD8 as monotherapy and in combination treatment with nivolumab in human leukocyte antigen (HLA) A2+ subjects with recurrent ovarian cancer positive for MAGE-A4.
Phase: PHASE2 • Sponsor: USWM CT, LLC • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Quantum eye test could catch blindness before it starts
Diagnosis Recruiting nowAge-related macular degeneration (AMD), is a debilitating eye disease that causes a loss of central vision. The prevalence of AMD increases exponentially with age and causes a significant impact through both medical expenses and the social and economic costs associated with visio…
Phase: NA • Sponsor: Centre for Eye and Vision Research • Aim: Diagnosis
Last updated Jun 27, 2026 11:03 UTC
-
New drug candidate BL-B01D1 targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowA phase Ib/II clinical study to evaluate the safety, tolerability, pharmacokinetics and efficacy of BL-B01D1 for injection in patients with multiple solid tumors, including recurrent or metastatic gynecological malignancies.
Phase: PHASE1, PHASE2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New hope for babies with rare calcification disease: first drug trial launches
Disease control Recruiting nowThe primary purpose of Study INZ701-104 (the ENERGY study) is to assess the safety and tolerability of INZ-701 in infants with ENPP1 Deficiency or with ABCC6 Deficiency.
Phase: PHASE1 • Sponsor: Inozyme Pharma • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Bladder cancer trial tests two new drug cocktails against standard combo
Disease control OngoingThis study is a substudy being conducted under one pembrolizumab umbrella master study KEYMAKER-U04. The substudy will consist of 2 parts. Part 1 will evaluate the efficacy and safety of coformulated favezelimab/pembrolizumab plus EV and coformulated vibostolimab/pembrolizumab pl…
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 26, 2026 16:06 UTC
-
New drug shows promise against fatty liver disease in major trial
Disease control CompletedThe purpose of this study is to learn how well efinopegdutide works compared to placebo in people who have non-alcoholic steatohepatitis (NASH). Researchers will also learn about the safety and benefit of efinopegdutide and how well people tolerate the medicine. The main goal of …
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC